Sanofi Africa
Sanofi in Deutschland is the Frankfurt am Main-based German subsidiary of Paris-listed global biopharma Sanofi S.A., distributing prescription medicines, vaccines, monoclonal antibodies, and biologics across more than 12 therapy areas via pharmacy, hospital, and prescription channels, supported by a multi-portal patient and medical-professional digital ecosystem.
- Company typePublic
- Founded2005
- HeadquartersKenyase, Ghana
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sanofi Africa does
Sanofi in Deutschland is the German country subsidiary of Sanofi S.A., a Paris-headquartered global biopharmaceutical company listed on Euronext Paris under ticker SAN. The German entity, with its main operations at the Sanofi BioCampus in Frankfurt am Main (Building K703) and a secondary office in Berlin, was established in 2005 and operates as a research-based biopharma company. It applies AI across research and development and distributes a broad portfolio of prescription medicines, vaccines, monoclonal antibodies for passive immunization, and biologics across more than a dozen therapy areas, including respiratory diseases, diabetes, cardiovascular disease, oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher disease, Morbus Scheie), transplant medicine, skin conditions, thyroid disorders, and eosinophilic esophagitis. Revenue is generated through regulated one-time prescription sales via pharmacy distribution networks, hospital and clinical channels, and the prescription drug channel within Germany.
The subsidiary runs a multi-channel digital ecosystem targeting patients and medical professionals, anchored by the mein.sanofi.de information portal (product database, FAQs, digital package inserts, training materials, videos), the eAcademy.sanofi.de professional education platform, the apothekenservice.sanofi.de pharmacy service portal, and a network of disease-specific patient-education websites covering diabetes, vaccines, atopic dermatitis, MS, asthma, nasal polyps, Gaucher disease, and thyroid conditions. Distribution flows through regulated pharmacy networks, direct hospital and clinical engagement for specialty products, and traditional prescription channels; pricing is regulated and not publicly disclosed, and the company engages end customers through information and education rather than direct-to-consumer sales.
Customer segments split primarily between patients and medical professionals (both flagged as primary in source), with pharmacy partners serving as a secondary channel for product ordering and customer care. The go-to-market is enterprise field sales directed at healthcare providers, hospitals, and pharmacies, supplemented by content marketing through Sanofi Today magazine, the Health x Tomorrow digitalization initiative, and disease-awareness content. Specific revenue, headcount, and deal-level figures for the German subsidiary are not disclosed in the available source material, and the entity functions as a country-level operating arm of the global Sanofi group rather than an independent investable company.
Sanofi Africa firmographics
Firmographics- Name
- Sanofi Africa
- Legal name
- Sanofi
- Website
- https://sanofi-aventis.de
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Sanofi in Deutschland is the Frankfurt am Main-based German subsidiary of Paris-listed global biopharma Sanofi S.A., distributing prescription medicines, vaccines, monoclonal antibodies, and biologics across more than 12 therapy areas via pharmacy, hospital, and prescription channels, supported by a multi-portal patient and medical-professional digital ecosystem.
- Ownership category
- akta.pro rank
Sanofi Africa industry classification
Industry- Product category
- Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Sanofi Africa is headquartered
LocationHeadquarters
- HQ city
- Kenyase
- HQ country
- Ghana
- HQ region
- Africa
Offices3 records
Markets served
Sanofi Africa business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Products: Revenue generated through prescription medicines, vaccines, and biopharmaceutical products across multiple therapy areas including respiratory diseases, diabetes, cardiovascular diseases, vaccines, oncology, multiple sclerosis, rheumatology, rare diseases, and transplant medicine.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Sanofi Africa product offering
Product offeringCore offering
Sanofi is a research-based biopharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, monoclonal antibodies for passive immunization, and biologics across multiple therapy areas including respiratory diseases, diabetes, cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases, transplant medicine, thyroid diseases, eosinophilic esophagitis, and skin diseases. The company applies artificial intelligence in its research and development operations and operates digital information portals for patients, medical professionals, and pharmacy partners.
Product overview
Sanofi is a research-based biopharma company that applies AI and offers a portfolio of therapeutic products across multiple disease areas. The company's product ecosystem includes mein.sanofi.de, a comprehensive patient and medical professional information portal offering product databases, package inserts, FAQs, and medical information services. Sanofi provides treatments across therapy areas including respiratory diseases, diabetes, skin diseases (atopic dermatitis), cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher, Morbus Scheie), transplant medicine, and thyroid diseases. The portfolio includes vaccines and monoclonal antibodies (mAk) for passive immunization. The company also offers digital package inserts and operates disease-specific websites for patient education. Sanofi leverages technology platforms and biologics development capabilities in its research and development operations.
Differentiator
Problem solved
Functional benefit
Brands
- mein.sanofi.de: Patient and medical professional information portal providing further information on therapy areas and products
Products and services
- mein.sanofi.de Patient and Medical Professional Information Portal Comprehensive information portal for patients and medical professionals providing detailed content on therapy areas and Sanofi products, including package inserts, FAQs, expert information (Fachinformationen), videos, and training materials.
- Sanofi Medical Information Portal (Medizinische Informationen) Medical information portal providing FAQs, stability calculators for vaccine and monoclonal antibody shelf life and storage, and ingredient search capabilities, targeted at medical professionals.
- apothekenservice.sanofi.de Pharmacy Service Portal Dedicated service portal for pharmacy partners to place orders, access product information, and engage with Sanofi customer care.
- eAcademy.sanofi.de Professional Training Platform Professional education and training platform for medical professionals, providing continuing education programs and training materials.
- Sanofi Vaccines Portfolio (Impfstoffe) Vaccine products for preventive immunization across various infectious disease areas, including vaccines with associated stability calculators for shelf life and storage.
- Sanofi Monoclonal Antibodies for Passive Immunization (Monoklonale Antikörper) Monoclonal antibody (mAk) products for passive immunization, supported by stability calculators through the medical information portal for shelf life and storage guidance.
- Sanofi Therapeutic Product Portfolio Prescription pharmaceutical products across multiple therapy areas: respiratory diseases (asthma, COPD), diabetes, cardiovascular diseases, oncology (including thyroid cancer), multiple sclerosis, rheumatology, rare diseases (Gaucher disease, Morbus Scheie), transplant medicine, eosinophilic esophagitis, and skin diseases (atopic dermatitis, neurodermitis).
- Biologics (Biologika) Biological medicines developed through Sanofi's biotechnology research platforms.
Companies that use Sanofi Africa
Customer profileSegments3 records
Ideal customer profiles3 records
Sanofi Africa technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Sanofi Africa partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights6 records
Sanofi Africa competitors and assessment
Company assessmentDirect peers
- Merck & Co. (MSD): US pharma leader in oncology (Keytruda) and vaccines, with comparable R&D scale and biologics capabilities. Direct peer in specialty pharma and immunology pipelines.
- Pfizer: Largest US pharma with broad portfolio including vaccines, oncology, and rare diseases. Direct competitor across multiple therapy areas where Sanofi operates.
- GSK (GlaxoSmithKline): UK-based pharma with one of the world's largest vaccines businesses and overlapping specialty medicines. Direct peer in vaccines, respiratory, and HIV/infectious disease.
- Roche: Swiss pharma giant with strong biologics/monoclonal antibody capabilities and overlapping oncology, immunology, and diagnostics portfolios. Direct competitor in specialty care and biologics manufacturing.
- Novartis: Swiss-headquartered global pharmaceutical company with overlapping therapeutic areas including oncology, immunology, and rare diseases. Comparable in scale, portfolio breadth, and AI-driven R&D investments.
- Bayer: German-headquartered pharma and consumer health company with overlapping cardiovascular, oncology, and women's health portfolios. Direct domestic peer with shared regulatory environment.
- Bristol Myers Squibb: US pharma with major oncology and immunology franchises plus cardiovascular history. Competes with Sanofi in specialty care and biologics.
- Eli Lilly: US pharma with diabetes (overlapping with Sanofi's Lantus franchise), oncology, and immunology. Direct competitor in diabetes care and emerging immunology/biologic markets.
- AstraZeneca: UK/Sweden-headquartered pharma with strong oncology, respiratory, and biologics franchises. Competes directly with Sanofi in respiratory diseases and immunology.
Regional players
- Boehringer Ingelheim: Privately held German pharmaceutical company headquartered in Ingelheim with overlapping respiratory and cardiometabolic portfolios. Regional peer sharing the same domestic market and regulatory framework as Sanofi in Deutschland.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Sanofi Africa social profiles
Digital presenceSanofi Africa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanofi Africa leadership team
Management profileNumber of profiles
Profiles5 records
Sanofi Africa funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanofi Africa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanofi Africa
What does Sanofi Africa do?
Sanofi is a research-based biopharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, monoclonal antibodies for passive immunization, and biologics across multiple therapy areas including respiratory diseases, diabetes, cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases, transplant medicine, thyroid diseases, eosinophilic esophagitis, and skin diseases. The company applies artificial intelligence in its research and development operations and operates digital information portals for patients, medical professionals, and pharmacy partners.
Is Sanofi Africa a public or private company?
Sanofi Africa is a public company. It is classified as public and is currently operating.
When was Sanofi Africa founded?
Sanofi Africa was founded in 2005. It employs 5,001 to 10,000 people.
Where is Sanofi Africa based?
Sanofi Africa is headquartered in Kenyase, Ghana, in the Africa region.
How does Sanofi Africa make money?
One revenue line is on record: pharmaceutical Products.
Who are Sanofi Africa's main competitors?
Direct peers on record are Merck & Co. (MSD), Pfizer, GSK (GlaxoSmithKline), Roche, Novartis, Bayer, Bristol Myers Squibb, Eli Lilly and AstraZeneca. Boehringer Ingelheim is listed as a regional player.
Does Sanofi Africa have an API?
No public API is recorded for Sanofi Africa.
What industry is Sanofi Africa in?
Sanofi Africa's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its SIC code is 2834.